148 related articles for article (PubMed ID: 11272165)
41. HNF1A：From Monogenic Diabetes to Type 2 Diabetes and Gestational Diabetes Mellitus.
Li LM; Jiang BG; Sun LL
Front Endocrinol (Lausanne); 2022; 13():829565. PubMed ID: 35299962
[TBL] [Abstract][Full Text] [Related]
42. Pregnancy in Women With Monogenic Diabetes due to Pathogenic Variants of the Glucokinase Gene: Lessons and Challenges.
Timsit J; Ciangura C; Dubois-Laforgue D; Saint-Martin C; Bellanne-Chantelot C
Front Endocrinol (Lausanne); 2021; 12():802423. PubMed ID: 35069449
[TBL] [Abstract][Full Text] [Related]
43. A multigenerational study on phenotypic consequences of the most common causal variant of HNF1A-MODY.
Kettunen JLT; Rantala E; Dwivedi OP; Isomaa B; Sarelin L; Kokko P; Hakaste L; Miettinen PJ; Groop LC; Tuomi T
Diabetologia; 2022 Apr; 65(4):632-643. PubMed ID: 34951657
[TBL] [Abstract][Full Text] [Related]
44. Precision Therapy for a Chinese Family With Maturity-Onset Diabetes of the Young.
Li J; Shu M; Wang X; Deng A; Wen C; Wang J; Jin S; Zhang H
Front Endocrinol (Lausanne); 2021; 12():700342. PubMed ID: 34421822
[TBL] [Abstract][Full Text] [Related]
45. The β Cell in Diabetes: Integrating Biomarkers With Functional Measures.
Kahn SE; Chen YC; Esser N; Taylor AJ; van Raalte DH; Zraika S; Verchere CB
Endocr Rev; 2021 Sep; 42(5):528-583. PubMed ID: 34180979
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA).
Christensen AS; Hædersdal S; Støy J; Storgaard H; Kampmann U; Forman JL; Seghieri M; Holst JJ; Hansen T; Knop FK; Vilsbøll T
Diabetes Care; 2020 Sep; 43(9):2025-2033. PubMed ID: 32661107
[TBL] [Abstract][Full Text] [Related]
47. Treatment Options for MODY Patients: A Systematic Review of Literature.
Delvecchio M; Pastore C; Giordano P
Diabetes Ther; 2020 Aug; 11(8):1667-1685. PubMed ID: 32583173
[TBL] [Abstract][Full Text] [Related]
48. GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers.
Christensen AS; Hædersdal S; Storgaard H; Rose K; Hansen NL; Holst JJ; Hansen T; Knop FK; Vilsbøll T
Diabetes; 2020 Sep; 69(9):1989-2002. PubMed ID: 32518064
[TBL] [Abstract][Full Text] [Related]
49. Genetics and Pathophysiology of Maturity-onset Diabetes of the Young (MODY): A Review of Current Trends.
Yahaya TO; Ufuoma SB
Oman Med J; 2020 May; 35(3):e126. PubMed ID: 32489678
[TBL] [Abstract][Full Text] [Related]
50. Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure.
Arslanian S; El Ghormli L; Haymond MH; Chan CL; Chernausek SD; Gandica RG; Gubitosi-Klug R; Levitsky LL; Siska M; Willi SM;
Pediatr Diabetes; 2020 Jun; 21(4):575-585. PubMed ID: 32064729
[TBL] [Abstract][Full Text] [Related]
51. Birthweight correlates with later metabolic abnormalities in Chinese patients with maturity-onset diabetes of the young type 2.
Fu J; Wang T; Liu J; Wang X; Li M; Xiao X
Endocrine; 2019 Jul; 65(1):53-60. PubMed ID: 31028668
[TBL] [Abstract][Full Text] [Related]
52. Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial.
Sidelmann Christensen A; Storgaard H; Hædersdal S; Hansen T; Knop FK; Vilsbøll T
BMJ Open; 2018 Oct; 8(10):e022517. PubMed ID: 30287671
[TBL] [Abstract][Full Text] [Related]
53. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
[TBL] [Abstract][Full Text] [Related]
54. When is it MODY? Challenges in the Interpretation of Sequence Variants in MODY Genes.
Althari S; Gloyn AL
Rev Diabet Stud; 2015; 12(3-4):330-48. PubMed ID: 27111119
[TBL] [Abstract][Full Text] [Related]
55. Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes.
Flannick J; Beer NL; Bick AG; Agarwala V; Molnes J; Gupta N; Burtt NP; Florez JC; Meigs JB; Taylor H; Lyssenko V; Irgens H; Fox E; Burslem F; Johansson S; Brosnan MJ; Trimmer JK; Newton-Cheh C; Tuomi T; Molven A; Wilson JG; O'Donnell CJ; Kathiresan S; Hirschhorn JN; Njølstad PR; Rolph T; Seidman JG; Gabriel S; Cox DR; Seidman CE; Groop L; Altshuler D
Nat Genet; 2013 Nov; 45(11):1380-5. PubMed ID: 24097065
[TBL] [Abstract][Full Text] [Related]
56. New opportunities: harnessing induced pluripotency for discovery in diabetes and metabolism.
Teo AK; Wagers AJ; Kulkarni RN
Cell Metab; 2013 Dec; 18(6):775-91. PubMed ID: 24035588
[TBL] [Abstract][Full Text] [Related]
57. Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies.
Steele AM; Wensley KJ; Ellard S; Murphy R; Shepherd M; Colclough K; Hattersley AT; Shields BM
PLoS One; 2013; 8(6):e65326. PubMed ID: 23799006
[TBL] [Abstract][Full Text] [Related]
58. Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene (MODY2).
Spégel P; Ekholm E; Tuomi T; Groop L; Mulder H; Filipsson K
Diabetes; 2013 Feb; 62(2):653-61. PubMed ID: 23139355
[TBL] [Abstract][Full Text] [Related]
59. Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign.
Fendler W; Borowiec M; Baranowska-Jazwiecka A; Szadkowska A; Skala-Zamorowska E; Deja G; Jarosz-Chobot P; Techmanska I; Bautembach-Minkowska J; Mysliwiec M; Zmyslowska A; Pietrzak I; Malecki MT; Mlynarski W
Diabetologia; 2012 Oct; 55(10):2631-2635. PubMed ID: 22782286
[TBL] [Abstract][Full Text] [Related]
60. Clinical assessment of HNF1A and GCK variants and identification of a novel mutation causing MODY2.
Shoemaker AH; Zienkiewicz J; Moore DJ
Diabetes Res Clin Pract; 2012 May; 96(2):e36-9. PubMed ID: 22341299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
